Cancer du pancréas, mutations BRCA 1/2 et inhibiteurs de PARP : l’étude POLO et après ? (notice n° 663455)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03348cam a2200373 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121193336.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | El Kurdi, Sara |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Cancer du pancréas, mutations BRCA 1/2 et inhibiteurs de PARP : l’étude POLO et après ? |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2021.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 7 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Une mutation germinale d’un gène BRCA1 ou BRCA2 est identifiée chez 5 % à 7 % des malades atteints de cancer du pancréas. Du fait de l’altération de la fonction de ces gènes, la réparation des cassures de l’ADN repose alors sur une voie alterne (PARP) dont l’inhibition peut aboutir à la mort cellulaire. L’étude de phase III POLO a montré que l’inhibiteur de PARP olaparib, administré en traitement de maintenance chez les malades ayant un cancer du pancréas métastatique avec mutation germinale BRCA1/2 et traités au préalable par chimiothérapie avec un sel de platine, peut augmenter significativement le temps de contrôle tumoral. Cette étude a généré des critiques et soulevé aussi des questions quant à la transposition de l’efficacité vis-à-vis des mutations somatiques des gènes BRCA 1/2 mais aussi des autres gènes de réparation de l’ADN. La prédictibilité de l’efficacité des inhibiteurs de PARP dans ces cancers et l’utilité de leur association aux immunothérapies doivent être étudiées. L’intérêt pour les thérapies ciblées sur des anomalies génétiques dans les cancers du pancréas ( BRCA 1/2 mais aussi NTRK, NRG1, MMR…) est relancé. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | A germline mutation of BRCA1 or BRCA2 genes is identified in 5% to 7 % of pancreatic cancer patients. Due to the altered function of these genes, DNA break repair then relies on an alternate pathway (PARP), the inhibition of which can then lead to cell death. The phase 3 POLO study showed that the PARP inhibitor olaparib, administered as maintenance treatment in metastatic pancreatic cancer patients with BRCA1/2 germline mutation and who's tumor has previously been controlled using a platinum-based chemotherapy, can significantly increase the tumor control time. This study generated criticisms and raised questions about the transposition of efficiency against somatic mutations in BRCA1/2 genes but also in other DNA repair genes. The predictability of the efficacy of PARP inhibitors in these tumors and the role of their combination with immunotherapies should be investigated. The interest in therapies targeted at genetic abnormalities in pancreatic cancers ( BRCA 1/2 but also NTRK, NRG1, MMR…) is relaunched. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | PARP |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | gènes |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | thérapie ciblée |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | BRCA1/2 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cancer du pancréas |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | genes |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | PARP |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | or |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | targeted therapies |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | pancreatic cancer |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | BRCA2 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | BRCA1 |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Sakouti, Djahida |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Colle, Élise |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hadj-Naceur, Imène |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Bouattour, Mohamed |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hammel, Pascal |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hépato-Gastro & Oncologie Digestive | 28 | 6 | 2021-06-01 | p. 731-738 | 2115-3310 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2021-6-page-731?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2021-6-page-731?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux